• To date the crystal structures of HIV IN complexed with

  2022-01-03

  

  To date, the crystal structures of HIV-1 IN complexed with ligands and related proteins could help us in studying the interactions between the inhibitors and IN. Until now, 114 co-crystal structures of HIV-1 IN with small molecular ligands 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,

• br Discussion Our study found that of MSM from

  2022-01-03

  

  Discussion Our study found that 62.6% of MSM from Natal had been tested for HIV before. This rate was higher than the national average of 37% estimated for the general carbenoxolone in 2011 and the 51.6% found by Brito et al. in MSM from 10 Brazilian cities in 2009. These rates are rather disapp

• Management of HIV treatment with HIV PIs

  2022-01-03

  

  Management of HIV-1 treatment with HIV PIs can be complicated due to wide inter-patient variability in Puromycin levels. In certain scenarios, therapeutic drug monitoring (TDM) has been recommended as a useful approach to individualize therapy for HIV-infected patients [[9], [10], [11], [12]]. Seve

• A compound structurally similar to PF has

  2022-01-03

  

  A pac 1 synthesis structurally similar to PF-03654746 has been developed by Pfizer (PF-03654764), with a minor change in the substituent attached to the cyclobutanecarboxamide moiety (Wager et al., 2011). This compound, with the chemical name trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phen

7984 records 533/533 page Previous First page 上5页 531532533